Similarly, a response to sunitinib 37,5 mg daily was demonstrated in a multicenter phase-II trial: 44% of chordoma patients achieved a SD concurrent to a qualitative decrease in tumor density; this pattern of response is considered to be characteristic of tumor response to VEGF-directed therapy (15). This evidence concerns the gene VEGFA and chordoma.